Search Results Label

Influenza is a common, highly contagious infection that can lead to life-threatening complications. Learn more about influenza and our cutting-edge vaccines.

https://www.seqirus.us/expertise/influenza

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

Results suggest that QIVc was more effective than QIVe at preventing IRMEs in both populations, with fewer documented IRMEs in children and adults.

https://www.seqirus.us/news/seqirus-presents-evidence-of-seasonal-influenza-vaccine-effectiveness-at-isirv

Seqirus announces data supporting the effectiveness of both cell-based and adjuvanted seasonal influenza vaccines from two real-world studies conducted during the 2019/2020 influenza season in the U.S.

https://www.seqirus.us/news/seqirus-presents-new-rwe-flu-vaccines-at-idweek

Seqirus is a world leader in developing and producing influenza vaccines. Learn more about how we work with our partners to protect the global community.

https://www.seqirus.us/products

Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives

https://www.seqirus.us/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines

With FDA approval, FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine in the U.S., is now indicated for everyone eligible to receive an influenza vaccine in the United States.

https://www.seqirus.us/news/seqirus-receives-fda-approval-for-flucelvax-quadrivalent-for-children-6-months-and-older

NEJM study indicates that the seasonal influenza vaccine was effective and produced a sufficient immune response against influenza in children and adolescents ≥2 to <18 years of age

https://www.seqirus.us/news/nejm-study-cell-based-quadrivalent-influenza-vaccine-efficacy-in-children

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic

https://www.seqirus.us/news/first-shipment-2021-22

Seqirus appoints Roberta Duncan as new program lead to drive technology advancement. Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza.

https://www.seqirus.us/news/seqirus-invests-in-self-amplifying-messenger-rna-technology